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Background: Interleukin 12 (IL-12) is a pivotal regulator of innate and adaptive immunity. We conducted a prospective
open-label, phase II clinical trial of electroporated plasmid IL-12 in advanced melanoma patients (NCT 01502293).
Patients and methods: Patients with stage III/IV melanoma were treated intratumorally with plasmid encoding IL-12
(tavokinogene telseplasmid; tavo), 0.5 mg/ml followed by electroporation (six pulses, 1500 V/cm) on days 1, 5, and
8 every 90 days in the main study and additional patients were treated in two alternative schedule exploration
cohorts. Correlative analyses for programmed death-ligand 1 (PD-L1), flow cytometry to assess changes in immune
cell subsets, and analysis of immune-related gene expression were carried out on pre- and post-treatment samples
from study patients, as well as from additional patients treated during exploration of additional dosing schedules
beyond the pre-specified protocol dosing schedule. Response was measured by study-specific criteria to maximize
detection of latent and potentially transient immune responses in patients with multiple skin lesions and toxicities
were graded by the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).
Results: The objective overall response rate was 35.7% in the main study (29.8% in all cohorts), with a complete
response rate of 17.9% (10.6% in all cohorts). The median progression-free survival in the main study was 3.7
months while the median overall survival was not reached at a median follow up of 29.7 months. A total of 46% of
patients in all cohorts with uninjected lesions experienced regression of at least one of these lesions and 25% had a
net regression of all untreated lesions. Transcriptomic and immunohistochemistry analysis showed that immune
activation and co-stimulatory transcripts were up-regulated but there was also increased adaptive immune resistance.
Conclusions: Intratumoral Tavo was well tolerated and led to systemic immune responses in advanced melanoma
patients. While tumor regression and increased immune infiltration were observed in treated as well as untreated/
distal lesions, adaptive immune resistance limited the response.
Key words: Immunotherapy, IL-12, Tavokinogene telseplasmid, intratumoral, melanoma, electroporation, cytokineINTRODUCTION
The cytokine interleukin 12 (IL-12) occupies a unique niche
in the cytokine repertoire bridging the innate and adaptive
immune systems.1 IL-12 is typically triggered upon
pathogen-associated molecular pattern or danger-
associated molecular pattern recognition and causes
secretion of interferon-g (IFN-g) by T cells, natural killer
(NK) cells, and dendritic cells (DCs), which in turn causes
additional IL-12 production by immune cells. IL-12 causes*Correspondence to: Prof. Adil I. Daud, Department of Medicine, University of
California, San Francisco, 1600 Divisadero Street, Rm A741, San Francisco, CA
94113, USA. Tel: +1-415-353-7392
E-mail: Adil.daud@ucsf.edu (A. I. Daud).
0923-7534/© 2020 The Authors. Published by Elsevier Ltd on behalf of Eu-
ropean Society for Medical Oncology. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Volume xxx - Issue xxx - 2020TH1 polarization, reduces regulatory T cells, and converts
myeloid-derived suppressor cells to functional DCs. In
addition, IL-12 (and IFN-g) are crucial third signals sent by
cross-presenting DC (cDC1) to naive CD8þ T cells, aiding
their transformation into effector T cells.2 Intravenous re-
combinant IL-12 (rIL-12) has shown clinical efficacy in solid
tumor malignancies including renal cell cancer3 and mela-
noma,4 albeit with a high level of serious adverse events
(AEs). Subcutaneous and intralesional recombinant cyto-
kines have a lower toxicity, but also a much lower efficacy.5
In contrast to intralesional and systemic rIL-12, intra-
tumoral injection of plasmid encoding IL-12 (Tavo) leads to
sustained cytokine elaboration in the tumor microenviron-
ment in vivo, with minimal systemic exposure. In the syn-
geneic B16 melanoma model, local IL-12 plasmid
electroporation causes regression of both established localhttps://doi.org/10.1016/j.annonc.2019.12.008 1
Annals of Oncology A. Algazi et al.and distant (non-treated) lesions, while yielding immune
memory to tumor rechallenge.6e8 A phase I clinical trial of
IL-12 plasmid electroporation established a biologically
effective dose and demonstrated the safety of this
approach, as well as its preliminary efficacy in increasing
intratumoral IL-12 and IFN-g, yielding sustained, global re-
missions in several patients after one cycle of therapy. We
evaluated Tavo for efficacy and safety in an open-label,
phase II trial.METHODS
Study design
This was a prospective, multicenter, open-label, phase II
trial (NCT01502293) evaluating the clinical efficacy and
safety of Tavo in melanoma patients.Patients
Eligible patients were required to be 18 years old with
pathologically documented melanoma, with Eastern Coop-
erative Oncology Group (ECOG) performance status of 0e2,
and an unresectable American Joint Committee on Cancer
(AJCC) stage IIIB, IIIC, or IV A, B, or C, and two or more
melanoma lesions accessible to electroporation. Any prior
therapy was permitted. Any treatment-related toxicities
resolved to grade 1 or better before study treatment.Treatment
Tavo (IL-12 plasmid, 0.5 mg/ml) was administered on days
1, 5, and 8 of each 90-day cycle (Figure 1) by intratumoral
injection at a dose volume of one-quarter of the calculated
lesion volume (minimum ¼ 0.1 ml).9 Electroporation was
carried out using six pulses of 1500 V/cm and a pulse width
of 100 ms at 1-second intervals (ImmunoPulse, OncoSec
Medical, Inc. San Diego, CA). Additional patients treated
with the same plasmid dose but on different schedules
(dose schedule exploration, supplementary Figure S1,
available at Annals of Oncology online) were included in the
translational and untreated lesion response analyses.Consented (N = 38) Eligible 
A
Regimen
i.t. Tavo-EP days 1, 5, 8
90 days
B
Figure 1. (A) CONSORT diagram with the screening and treatment assignments of
injected at a dose-volume of one-quarter of the calculated lesion volume. Patien
response assessments were made every 90 days.
EP, electroporation; i.t., intratumoral.
2 https://doi.org/10.1016/j.annonc.2019.12.008Efficacy assessment
Tumor lesions and tumor response were assessed by the
investigator according to a modified version of RECIST
version 1.0 that allowed inclusion of any number of skin
lesions >0.3 cm at the largest diameter to be followed as
target lesions, inclusion of latent responses, and assessment
of the net tumor burden in the setting of new lesions.
Progression-free survival was assessed as the time from the
first day of study treatment until the time that the sum of
the diameters of all measurable lesions increased by at least
30% from baseline. Additional information regarding
response measures for treated and untreated lesions is
provided in the supplementary Materials, available at
Annals of Oncology online.Safety evaluation
Safety was assessed by monitoring AEs, pain assessments,
clinical laboratory tests, and vital signs. AEs were graded
according to the National Cancer Institute (NCI) Common
Terminology Criteria for Adverse Events (CTCAE), Version
4.0.Translational medicine and statistical plan
See the supplementary Materials, available at Annals of
Oncology online.
RESULTS
Baseline patient characteristics
For the main study, 38 patients were consented and 30
were eligible for the study and received at least one dose of
treatment (Table 1). Of these, 28 patients were assessable
for response (one withdrew before post-treatment assess-
ment, one was deemed ineligible after initiation of treat-
ment). Prior exposure to immunotherapy included 13
patients treated previously with systemic cytokines (high
dose IL-2 or IFNa-2a), nine patients treated with
anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
antibodies and four patients (13.3%) treated with anti-
programmed cell death protein 1 (PD-1) antibodies. In(N = 30)
i.t. Tavo-EP
Day 1, 5, 8
Every 90 days
(N = 30)
patients consented to study. (B) Tavokinogene telseplasmid (0.5 mg/ml) was
ts were treated on days 1, 5, and 8 of every 90-day treatment cycle. Tumor
Volume xxx - Issue xxx - 2020
Table 1. Patient demographics and patient history
Age Mean (SD) 66.8 (10.19)
Sex Male
Female
16 (53.3%)
14 (46.7%)
ECOG PS 0
1
21 (70.0%)
9 (30.0%)
Stage IIIb
IIIc
IV M1a
IV M1b
IV M1c
6 (20.0%)
13 (43.3%)
8 (26.7%)
3 (10.0%)
0
BRAF status Mutant
Wild-type
Unknown
10 (33.3%)
13 (43.3%)
7 (23.4%)
Prior therapy Cytokine
CTLA-4
PD-1/PD-L1
Cytokine þ CTLA-4
BRAF/MEK
Other
13 (43.3%)
9 (26.7%)
4 (13.3%)
1 (3.3%)
3 (10%)
5 (16.7%)
Prior lines 0
1
2þ
10 (33.3%)
10 (33.3%)
10 (33.3%)
N ¼ 30
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ECOG, Eastern Cooperative
Oncology Group; PD-1, programmed cell death protein 1; PD-L1, programmed
death-ligand 1; PS, performance status; SD, standard deviation.
A. Algazi et al. Annals of Oncologyaddition, 24 patients were screened and 21 additional pa-
tients were treated in the schedule exploration cohorts
(demographics are described in supplementary Table S1,
available at Annals of Oncology online).Table 2. All treatment-emergent adverse events observed in at least two patien
Category Toxicity Grade 1
All 10 (33.3%
Gastrointestinal Nausea
Vomiting
Diarrhea
4 (13.3%)
2 (6.7%)
1 (3.3%)
Constitutional Fatigue
Injection site discoloration
Injection site inflammation
Chills
Injection site discharge
Injection site erythema
Edema peripheral
Pain
Pyrexia
4 (13.3%)
4 (13.3%)
3 (10.0%)
2 (6.7%)
2 (6.7%)
2 (6.7%)
2 (6.7%)
e
2 (6.7%)
Infectious Cellulitis e
Procedural Procedural pain 23 (76.7%
Musculoskeletal Pain in extremity
Arthralgia
Muscle spasms
Musculoskeletal stiffness
4 (13.3%)
2 (6.7%)
2 (6.7%)
2 (6.7%)
Neoplasms Neoplasms NOS e
Nervous system Headache
Dizziness
Cerebrovascular accident
4 (13.3%)
2 (6.7%)
e
Psychiatric Anxiety 1 (3.3%)
Respiratory Cough 1 (3.3%)
Cutaneous Pruritus
Rash
Ecchymosis
Skin disorder
2 (6.7%)
3 (10.0%)
2 (6.7%)
1 (3.3%)
Vascular Lymphedema 2 (6.7%)
NOS, not otherwise specified.
N ¼ 30.
Volume xxx - Issue xxx - 2020AEs
All treatment-emergent AEs (TEAEs) regardless of attribution
observed in at least two patients and all grade 3 or higher
TEAEs are described in Table 2.Transient procedural pain (n¼
24, 80%) and injection site reactions were common. Consti-
tutional symptoms were observed in a minority of patients
including fatigue (n ¼ 5, 16.7%), pyrexia (n ¼ 2, 6.7%), and
chills (n ¼ 2, 6.7%). Grade 3 TEAEs were limited to transient
procedural pain (n¼ 1, 3.3%) and a cerebrovascular accident
that was determined to be unrelated to treatment on study. A
patient in one of the schedule exploration cohorts also had
grade 3, treatment-related cellulitis (supplementary Table S2,
available at Annals of Oncology online).Clinical response
The best overall response rate at any time point for Tavo
treatment in the main study population (cohort A) was 35.7
% (waterfall plot, Figure 2A). Seven patients had disease
progression before the first response assessment at 90 days
and are represented as having a 100% change in tumor
burden for graphic purposes. Responses included five
complete responses and responses in patients with exten-
sive in-transit/satellite metastases (Figure 2E and F). The
clinical response rate was 26.7% in cohort B (4/15) and
none of the four patients treated in cohort C responded.
The best overall response rate for patients in all cohorts wasts and all grade 3 or higher adverse events
Grade 2 ‡ Grade 3 All
grades
) 15 (50.0%) 4 (13.3%) 29 (96.7%)
1 (3.3%)
2 (6.7%)
2 (6.7%)
e
e
e
5 (16.7%)
4 (13.3%)
3 (10.0%)
1 (3.3%)
e
1 (3.3%)
e
e
e
e
2 (6.7%)
e
e
e
e
e
e
e
e
e
e
5 (16.7%)
4 (13.3%)
4 (13.3%)
2 (6.7%)
2 (6.7%)
2 (6.7%)
2 (6.7%)
2 (6.7%)
2 (6.7%)
2 (6.7%) e 2 (6.7%)
) e 1 (3.3%) 24 (80.0%)
1 (3.3%)
1 (3.3%)
e
e
e
e
e
e
5 (16.7%)
3 (10.0%)
2 (6.7%)
2 (6.7%)
2 (6.7%) e 2 (6.7%)
1 (3.3%)
e
e
e
e
1 (3.3%)
5 (16.7%)
2 (6.7%)
1 (3.3%)
2 (6.7%) e 3 (10.0%)
1 (3.3%) e 2 (6.7%)
1 (3.3%)
e
e
1 (3.3%)
e
e
e
e
3 (10.0%)
3 (10.0%)
2 (6.7%)
2 (6.7%)
e e 2 (6.7%)
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Figure 2. (A) Best overall response in all assessable patients (n[ 28) assessed as the sum of diameters of target lesions by a modified version of RECIST version
1.0 (*[ disease progression due to progression of non-targets). (B) A spider plot demonstrating durables and transient responses in responding patients (n[ 8).
(C) KaplaneMeier plots for progression-free survival (PFS) and (D) overall survival (OS). The median PFS was 3.7 months (95% confidence interval 0.6e6.9 months)
and the median OS was not reached at a median follow-up of 29.7 months. (E) A patient with extensive satellite lesions before treatment demonstrates (F)
complete regression of treated and untreated lesions by day 270.
Annals of Oncology A. Algazi et al.29.8% (supplementary Figure S2, available at Annals of
Oncology online). Per-patient lesion and response data are
presented in supplementary Table S3, available at Annals of
Oncology online.Adaptive resistance and response to checkpoint therapy
The median progression-free survival was 3.72 months
[95% confidence interval (CI) 0.55e6.89], 3.2 months (95%
CI 2.41e3.97), and 2.5 months (95% CI not defined) in
cohorts A (main study), B, and C, respectively. The median
overall survival was not reached in any cohort (Figure 2C
and D, supplementary Figure S2B, available at Annals of4 https://doi.org/10.1016/j.annonc.2019.12.008Oncology online). Treatment with Tavo induced adaptive
resistance as demonstrated by increases in programmed
death-ligand 1 (PD-L1) expression by immunohistochem-
istry (Figure 3A). As a possible consequence, although
durable responses were seen in four patients, transient
responses were observed in six others (Figure 2B). In some
patients, however, Tavo increased the total number of
tumor infiltrating lymphocytes and the CD8:FoxP3 ratio
suggesting an increase in the relative abundance of
effector T cells versus regulatory cells (e.g. Figure 3CeE),
and, in a retrospective analysis, six of eight patients pro-
gressing on Tavo responded to pembrolizumab immedi-
ately thereafter (Figure 3B, FeJ).Volume xxx - Issue xxx - 2020
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Figure 3. (A) Treatment with tavokinogene telseplasmid was associated with an increase in PD-L1 IHC scores suggesting induction of adaptive resistance. (B)
Responses to Tavo and subsequent anti-PD-1 antibody therapy in 8 patients treated with Tavo followed immediately by an anti-PD1 antibody (f denotes patient
response assessed by FDG-PET). (CeE) Treatment with Tavo was associated with an increase in CD8D cells and an increase in the CD8D:Foxp3D cells in a
responding patient. (FeJ) A patient with a transient response to Tavo followed by a durable response to pembrolizumab by FDG-PET.
FDG, [18F]2-fluoro-2-deoxy-D-glucose; IHC, immunohistochemistry; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PET, positron emission
tomography.
A. Algazi et al. Annals of OncologyInflammatory gene expression
Tavo induced significant increases in multiple immune
transcripts (Figure 4A), including modules associated withVolume xxx - Issue xxx - 2020immune activation (Figure 4B), NK cell activity, antigen
presentation and adaptive resistance (Figure 4C), as well as
T cell trafficking (Figure 4D); all characteristic of anhttps://doi.org/10.1016/j.annonc.2019.12.008 5
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Figure 5. Signs of systemic immune activity after treatment with tavokinogene telseplasmid (Tavo). Tavo increased circulating levels of (A) IL-1b and (B) MIP-1a as
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A. Algazi et al. Annals of Oncologyantitumor immune response. Specific findings included
increased expression of CD3E, CD8, STAT4, IL-2RB and IL-
12RB1 as well as effector molecules such as GZMA,
consistent with the known effect of IL-12 on T cell and NK
cell activation.1 A significant increase in transcripts associ-
ated with cross-presenting DCs10 such as CIITA, BATF3,
PSMB7 and TAPBP111 were also noted. Additionally, the
chemokine receptor CXCR3, expressed on TH1-polarized T
cells, as well as chemokines and adhesion molecules were
significantly increased. However, this global increase in
genes associated with productive antitumor immunity was
accompanied by increases in genes associated with adap-
tive resistance including CD274 (PD-L1), TRFB1 and TRAIL.
IFN-g gene expression increased overall in patientsFigure 4. Tavokinogene telseplasmid-induced productive antitumor immune respon
transcriptional analysis of biopsies collected at screening and post-treatment. In par
(C) natural killer (NK) cell activity, antigen presentation, adaptive resistance, an
expression increased overall and in patients benefitting from treatment, but not
including 14 patients with pre-/post-biopsy specimens).
IFN, interferon.
Volume xxx - Issue xxx - 2020benefitting from treatment, but not in patients with pro-
gressive disease as the best treatment response (Figure 4E).
Overall, these results suggest that Tavo induced NK cell and
DC activation, recruitment, and activation of CD4þ T cell
and CD8þ T cells, as well as the compensatory develop-
ment of adaptive resistance.
Systemic immune response
We assessed systemic immune activity after treatment with
Tavo. Analysis of serum inflammatory markers showed an
increase in IL-1b and MIP-1a in responders but not in non-
responders (Figure 5A and B). Systemic increases were seen
in proliferating effector memory CD8þ T cells (Ki-
67þCCR7CD45RA, Figure 5C) and in circulating cytolyticses. (A) Volcano plot of both non-responding and responding patients based on
ticular, intratumoral expression of genes associated with (B) immune activation
d (D) T cell trafficking was increased after treatment. (E) Interferon-g gene
in patients with progressive disease as the best treatment response (n [ 28
https://doi.org/10.1016/j.annonc.2019.12.008 7
Annals of Oncology A. Algazi et al.NK cells (CD56dimCD16þ, Figure 5D) in responding but not
in non-responding patients (P < 0.05).
For patients in the main study and expansion cohorts,
responses in untreated lesions were common. In 40 pa-
tients with uninjected pre- and post-treatment tumor
measurements available, the best overall response for un-
treated lesions was 25% (n ¼ 40, Figure 5F) compared with
a 43.8% response rate in treated lesions (n ¼ 45 patients,
Figure 5E). The per-lesion response rate for treated lesions
was 62.7% (64/102) and for untreated lesions it was 17.4%
(20/115).
DISCUSSION
Prior therapeutic approaches to rIL-12, including intrale-
sional and systemic administration, have had limited effi-
cacy due to transient exposures associated with
intralesional therapy12 and severe toxicity associated with
systemic administration.13 We previously described a phase
I intratumoral dose-escalation pIL-12 electroporation trial
demonstrating that a plasmid concentration of 0.5 mg/ml
was well tolerated and showed clinical effectiveness with
abscopal responses and systemic immune activation.9 In the
current report, we confirm these findings in a phase II
expansion, demonstrating a 35.7% overall response rate in
the main study and a 29.8% overall response rate in all
cohorts.
Recently, several intratumoral therapies have been
explored, either in combination or alone, with a goal of
demonstrating that an ‘in situ’ immunization strategy can
yield systemic immune effects. For example, a retrospective
analysis of the modified herpes virus, Talimogene laher-
parepvec, administered intratumorally, demonstrated an
objective response rate of 26%,14,15 with regression of some
baseline uninjected lesions.16 In the current phase II trial of
Tavo, we used different response criteria, but regression of
treated lesions was common. Overall, Tavo induced
regression of at least one uninjected lesion in nearly half of
patients, demonstrating clinical evidence of systemic anti-
tumor immunity. In addition, a major benefit of the plasmid
electroporation platform is that it can be modified relatively
easily, based on translational data, to create next-
generation therapies. Indeed, preclinical testing of a next-
generation plasmid that induces expression of IL-12,
CXCL9, and tumor membrane-anchored anti-CD3 is
ongoing.17
Intratumoral Tavo electroporation was well tolerated,
and it did not induce the systemic symptoms associated
with intravenous cytokine administration and even consti-
tutional symptoms were mild and infrequent. No grade 4
adverse effects were noted, and only six patients had grade
3 adverse effects (local pain, five patients and cellulitis, one
patient). While systemic cytokine administration induces
fever, chills, and pyrexia suggesting a systemic inflammatory
response, despite a high rate of regression of untreated
lesions, these symptoms were not observed in patients
treated with Tavo.
Intratumoral IL-12, as generated by Tavo, induces cDC1
and establishes DC-T cell crosstalk that mediates tumor8 https://doi.org/10.1016/j.annonc.2019.12.008rejection.18 Since cDC1 play a crucial role in recruiting and
activating CD8þ T cells into the tumor microenviron-
ment10,11,18 and are in turn induced by NK cells,18 we
explored the effect of Tavo, in this publication, in a study by
Garris et al.,19 and in combination with PD-1 (manuscript
submitted for review). Tavo induces activation across mul-
tiple classes of immune transcripts (Figure 4), including
immune activation (Figure 4B), NK cell (Figure 4C), and
antigen presentation (Figure 4D). The immune activation
produced by Tavo results in both increased inflammatory
gene expression, including expression of IFN-g associated
genes, and adaptive immune resistance, with increased
expression of PD-L1 and TGFb. This induction of adaptive
resistance through PD-1/PD-L1 could explain the high pro-
portion of responses to subsequent PD-1 blockade in pa-
tients progressing on Tavo (Figure 3B). Based on these
findings, patients have now been treated on two prospec-
tive phase II clinical trials of Tavo in combination with the
anti-PD-1 antibody pembrolizumab. A study of patients with
few partially exhausted (PD1hiCTLA-4hiCD8þ) cells has been
completed and results will be reported elsewhere (sub-
mitted for publication) and a larger single-arm study in
patients with documented progression on PD-1 blockade
(KEYNOTE-695) is currently ongoing.
In summary, Tavo treatment drives changes in the immune
microenvironment resulting in both local and global immune
responses with minimal systemic toxicity. Our data demon-
strate that this in situ tumor vaccination strategy can be a
safe and effective approach to inducing multiple sustained,
productive changes in the immune microenvironment that
would be too toxic using similar systemic agents.
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